The price of Novavax, Inc (NASDAQ:NVAX) shares last traded on Wall Street rose 11.43% to $6.24.
NVAX stock price is now -20.63% away from the 50-day moving average and -39.76% away from the 200-day moving average. The market capitalization of the company currently stands at $1.00B.
With the price target of $19, BTIG Research recently initiated with Buy rating for Novavax, Inc (NASDAQ: NVAX). On July 30, 2024, JP Morgan Downgraded its previous ‘Neutral’ rating to ‘Underweight’ on the stock keeping its target price maintained at $8, while ‘BofA Securities’ rates the stock as ‘Neutral’
In other news, King Rachel K., Director sold 4,150 shares of the company’s stock on Dec 13 ’24. The stock was sold for $37,435 at an average price of $9.02. Upon completion of the transaction, the Director now directly owns 14,770 shares in the company, valued at $92164.8. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 31 ’24, Director YOUNG JAMES F sold 5,400 shares of the business’s stock. A total of $43,200 was realized by selling the stock at an average price of $8.00. This leaves the insider owning 51,760 shares of the company worth $0.32 million. A total of 8.87% of the company’s stock is owned by insiders.
During the past 12 months, Novavax, Inc has had a low of $3.81 and a high of $23.86. The fifty day moving average price for NVAX is $7.8616 and a two-hundred day moving average price translates $10.3582 for the stock.
The latest earnings results from Novavax, Inc (NASDAQ: NVAX) was released for 2024-12-31. The company reported revenue of $88.31 million for the quarter, compared to $291.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -69.69 percent.
